

# H PYLORI ANTIBIOTIC RESISTANCE: PREVALENCE, IMPORTANCE, AND ADVANCES IN TESTING

F Mégraud

1374

Gut 2004;53:1374–1384. doi: 10.1136/gut.2003.022111

The discovery that *Helicobacter pylori* infection is the main cause of most gastroduodenal diseases has been a major breakthrough in gastroenterology. It has dramatically changed the management of these diseases which are now considered as infectious diseases and are treated with antibiotics.

Triple therapy, including two antibiotics, amoxicillin and clarithromycin, and a proton pump inhibitor given for a week has been recommended as the treatment of choice at several consensus conferences.<sup>1–6</sup> However, this treatment may fail for several reasons, as reported elsewhere.<sup>7</sup> In fact, the main reason for failure was found to be *H pylori* resistance to one of the antibiotics used (that is, clarithromycin). Other treatments have also been proposed, including metronidazole, a drug for which resistance is also a problem although to a lesser extent, as well as tetracycline, fluoroquinolones, and rifamycins for which resistance has become an emerging issue.<sup>8–9</sup>

Our aim was to review the prevalence of *H pylori* resistance to these various antibiotics, their clinical importance, and methods of testing, especially in light of the resistance mechanism which allows application of molecular methods.

## PREVALENCE OF H PYLORI RESISTANCE TO ANTIBIOTICS

Numerous studies have been performed to determine the prevalence of *H pylori* resistance to antibiotics. However, many of them have drawbacks, in particular concerning the number and representativeness of the strains tested.

Most of the studies were performed in specialised centres, with recruitment of special cases which are not always representative of patients as a whole and, because these studies are monocentric, the number of patients may be low, leading to wide confidence intervals of the prevalence rates obtained.

Ideal studies involving patients who are representative of a given region are few. An alternative has been to analyse prevalence data obtained from clinical trials aiming to evaluate new regimens. As prevalence is in essence an evolving phenomenon, only the most recent articles have been taken into account in this review. However, given the delay in publication, only data from the end of the last decade are essentially available.

### Prevalence of *H pylori* resistance to clarithromycin

Only primary resistance has been reviewed, and adults and children were considered separately. An important difference is noted between the Northern and Southern parts of Europe (table 1). For adults in Northern Europe, the global prevalence was less than 5% while in Southern Europe it was as high as up to 20% or more. For children from all European countries a high prevalence has also been reported, ranging from 12.4% to 23.5% (table 2).

A prospective multicentre survey was also carried out in Europe in 1998. Investigators from 22 different centres located in 17 countries were involved and used a similar protocol, with Etest as the testing method. Overall, the minimum inhibitory concentrations (MICs) of 1274 isolates were determined with a mean of 64 isolates per centre, ranging from 21 to 115. The global primary resistance rate for clarithromycin was 9.9% (95% confidence interval (CI) 8.3–11.7). Interestingly, when the results were broken down according to the different regions in Europe, significant differences were observed which are in line with the data indicated above (that is, the prevalence of clarithromycin resistance in Northern Europe was low (4.2% (95% CI 0–10.8)), it was higher in Central/Eastern Europe (9.3% (95% CI 0–22)), and was the highest in Southern Europe (18% (95% CI 2.1–34.8)).<sup>44</sup>

A similar survey involving children in Europe was carried out more recently. Investigators from 16 paediatric centres from 14 countries collected their data over a four year period (1999–2002). A primary resistance rate of 24% was obtained (Koletzko, personal communication). A retrospective survey was also performed in Eastern Europe by Boyanova and colleagues.<sup>45</sup> Results on antibiotic resistance from 18 centres in Eastern European countries were gathered from 1998 to 2000 (1337 isolates). The prevalence of clarithromycin resistance was 9.5% (95% CI 7.9–11.1) with no

Correspondence to:  
F Mégraud, Laboratoire de  
Bactériologie, Hôpital  
Pellegrin, Place Amélie  
Raba-Léon, 33076 Bordeaux  
Cedex, France;  
francis.megraud@  
chu-bordeaux.fr

**Table 1** Primary resistance of *Helicobacter pylori* to clarithromycin, metronidazole, tetracycline, and amoxicillin in adults in different parts of the world

| Country         | Years | Type of study | Method of testing | No of strains tested | Clari <sup>R</sup> global prevalence (%) | 95% CI    | Metro <sup>R</sup> global prevalence (%) | 95% CI    | Tetra <sup>R</sup> global prevalence (%) | Amoxi <sup>R</sup> global prevalence (%) | Reference                        |
|-----------------|-------|---------------|-------------------|----------------------|--|-----------|--|-----------|--|--|----------------------------------|
| Europe          |       |               |                   |                      |  |           |  |           |  |  |                                  |
| Bulgaria        | 96–98 | TriC          | DD                | 103*                 | 8.7                                      | 4.1–15.9  | ND                                       |           | ND                                       | ND                                       | Boyanova <sup>10</sup>           |
| Croatia         | 2001  | MonoC         | Ettest            | 196                  | 8  | 4.7–12.9  | 33                                       | 26.6–40.2 | ND                                       | 0  | Bago <sup>11</sup>               |
| France          | 96–99 | MultiC        | AD                | 659                  | 15                                       | 12.4–18.0 | 31.5                                     | 28.0–35.3 | ND                                       | 0  | Mégraud <sup>12</sup>            |
| Germany         | 95–00 | MonoC         | Ettest            | 1644                 | 2.2                                      | 1.5–3.0   | 26.2                                     | 24.1–28.4 | 0  | 0  | Walle <sup>13</sup>              |
| Germany         | 95–96 | MultiC        | Ettest            | 188                  | 4  | 1.9–8.2   | 32                                       | 25.3–39.1 | ND                                       | ND                                       | Dammann <sup>14</sup>            |
| Italy (Central) | 98–02 | MonoC         | AD                | 406                  | 23.4                                     | 19.4–27.8 | 36.7                                     | 32.0–41.6 | ND                                       | 0.2                                      | Toracchio <sup>15</sup>          |
| Italy (North)   | 99    | MultiC        | Ettest            | 167                  | 1.8                                      | 0.4–5.2   | 14.9                                     | 9.9–21.3  | ND                                       | 0  | Piloto <sup>16</sup>             |
| Netherlands     | 97–98 | MultiC        | Ettest            | 231                  | 1.7                                      | 0–3.4     | 21.2                                     | 16.1–27.1 | 0  | 0  | Debets-Ossenkopp <sup>17</sup>   |
| Portugal        | 90–99 | TriC          | Ettest            | 132                  | 22                                       | 15.2–30.0 | 34.1                                     | 26.1–42.8 | 0  | 0  | Cabrita <sup>18</sup>            |
| Spain           | 95–98 | MonoC         | Ettest            | 235                  | 12.9                                     | 8.7–17.7  | 23.5                                     | 18.1–29.3 | 0.7                                      | 0  | Cuchi Burgos <sup>19</sup>       |
| Sweden          | 97–98 | MultiC        | AD                | 203                  | 2.9                                      | 1.1–6.3   | 26.1                                     | 20.2–32.6 | ND                                       | 0  | Mégraud <sup>12b</sup>           |
| UK              | 94–99 | MonoC         | DD                | 1064                 | 4.4†                                     | 3.3–5.8   | 40.3                                     | 37.4–43.3 | 0.5                                      | 0  | Parsons <sup>21</sup>            |
| UK              | 95–98 | MonoC         |                   | 843                  | 3.9                                      | 2.7–5.5   | 36                                       | 32.7–39.3 | ND                                       | 0.4                                      | Teare <sup>22</sup>              |
| North America   |       |               |                   |                      |  |           |  |           |  |  |                                  |
| Mexico          | 95–97 | MonoC         | Ettest            | 144                  | 25                                       | 18.2–32.9 | 76.3                                     | 68.6–83.1 | ND                                       | 0†                                       | Torres <sup>23</sup>             |
| USA             | 93–99 | MultiC        | AD                | 3439                 | 10.6                                     | 9.6–11.7  | 21.6                                     | 20.2–23.0 | ND                                       | 0.08                                     | Osato <sup>24</sup>              |
| USA             | 98–99 | MultiC        | AD                | 422                  | 12                                       | 9.1–15.6  | ND                                       |           | ND                                       | 0  | Laine <sup>25</sup>              |
| USA             | 00–01 | MultiC        | AD                | 106                  | 12.2                                     | 6.7–20.0  | 33.9                                     | 25.0–43.8 | ND                                       | ND                                       | Laine <sup>26</sup>              |
| South America   |       |               |                   |                      |  |           |  |           |  |  |                                  |
| Brazil          | 96–00 |               | AD                | 203                  | 9.8                                      | 6.1–14.8  | 53                                       | 46.1–60.2 | ND                                       | ND                                       | Prazeres-Magalhaes <sup>27</sup> |
| Middle East     |       |               |                   |                      |  |           |  |           |  |  |                                  |
| Iran            | 02    | BiC           | DD                | 120                  | 17                                       | 10.5–24.6 | ND                                       |           | ND                                       | ND                                       | Mohammadi <sup>28</sup>          |
| Israel          | 00–01 | MonoC         | Ettest            | 110                  | 8.2                                      | 3.8–15.0  | 38.2                                     | 29.1–47.9 | 0  | 0.9                                      | Samra <sup>29</sup>              |
| Far East        |       |               |                   |                      |  |           |  |           |  |  |                                  |
| Hong Kong       | 97–01 | MonoC         | DD                | 991                  | 4.5                                      | 3.3–6.0   | 29                                       | 26.3–32.0 | 0.5                                      | 0.3                                      | Ling <sup>30</sup>               |
| Japan           | 95–00 | MonoC         | AD                | 593                  | 11                                       | 8.6–13.8  | 9  | 6.8–11.5  | ND                                       | 0.3                                      | Perez Aldana <sup>31</sup>       |
| Japan           | 96–99 | BiC           | AD                | 388                  | 12.9                                     | 9.7–16.6  | 12.4                                     | 9.3–16.1  | ND                                       | 0  | Kato <sup>32</sup>               |
| Korea           | 94–99 | BiC           | AD                | 456                  | 5.9                                      | 3.9–8.5   | 40.6                                     | 36.0–45.2 | 5.3                                      | 0  | Kim <sup>33</sup>                |
| Korea           | 96–00 | MonoC         | BD                | 224                  | 5.4                                      | 2.8–9.2   | 41.9                                     | 35.4–48.7 | ND                                       | ND                                       | Eun <sup>34</sup>                |
| Singapore       | 93–96 | MonoC         |                   | 459                  | ND                                       |           | 62.7                                     | 58.1–67.2 | ND                                       | ND                                       | Teo <sup>35</sup>                |
| Singapore       | 02    | MonoC         | AD                | 120                  | ND                                       |           | 31.7                                     | 23.5–40.8 | ND                                       | ND                                       | Lui <sup>36</sup>                |
| New Zealand     | 93–98 | MonoC         | DD                | 225                  | 6.8                                      | 3.8–10.8  | 32                                       | 26.0–38.5 | ND                                       | ND                                       | Fraser <sup>37</sup>             |

Data from studies including more than 100 strains published during the last five years.

\*Includes 42 children.

†Transient resistance was observed in 19% of the strains.

‡Clarithromycin susceptibility performed on 812 strains only.

DD, disk diffusion method; AD, agar dilution method; BD, broth dilution method; ND, not determined; 95% CI, 95% confidence interval; C, centre.

Clari<sup>R</sup>, clarithromycin resistant; Metro<sup>R</sup>, metronidazole resistant; Tetra<sup>R</sup>, tetracycline resistant; Amoxi<sup>R</sup>, amoxicillin resistant.

significant difference between the different countries. Outside Europe, the prevalence of clarithromycin resistance tends to be lower. A systematic review of the studies performed in Canada before the year 2000 estimated resistance to be less than 4%.<sup>46</sup> However, it has already reached 10–15% in the USA based on data from clinical trials and regardless of the region. In the Middle East, a prevalence of 5.4% in Israel<sup>29</sup> and 17% in Iran<sup>28</sup> have been reported. In the Far East, the prevalence is higher in Japan (11–12%) than in Hong Kong (4.5%) and Korea (5–6%) (table 1).

Most of the studies provide data over several years and therefore it is possible to see the evolution of resistance.

However, the number of strains per year is usually low, so only a trend can be considered, and this trend is towards an increased prevalence over time.

The essential risk factor for clarithromycin resistance is previous consumption of macrolides,<sup>12 18</sup> and if resistance is higher in children it is because there was increased prescription of these drugs, notably in children during the last decade essentially for respiratory tract infections. A study in Japanese families showed that despite the fact that the children's strains were usually identical to one parent strain by molecular fingerprinting, the children's strains often became clarithromycin resistant after clarithromycin

**Table 2** Primary resistance of *Helicobacter pylori* to clarithromycin, metronidazole, and amoxicillin in children in Europe

| Country  | Years     | Type of study | Method of testing | No of strains | Clari <sup>R</sup> prevalence (%) | 95% CI    | Metro <sup>R</sup> prevalence (%) | 95% CI    | Amoxi <sup>R</sup> prevalence (%) | Reference                           |
|----------|-----------|---------------|-------------------|---------------|-----------------------------------|-----------|-----------------------------------|-----------|-----------------------------------|-------------------------------------|
| Austria  | 1997–2000 | BiC           | Ettest            | 117           | 20.3                              | 13.6–29   | 16                                | 10.1–24.2 | 0                                 | Crone <sup>38</sup>                 |
| Belgium  | 1989–2000 | MonoC         | DD                | 555           | 16                                | 13.1–19.4 | 18                                | 14.9–21.5 | 0                                 | Bontems <sup>39</sup>               |
| Bulgaria | 2000–2001 | MonoC         | AD                | 115           | 12.4                              | 6.8–19.6  | 15.8                              | 9.5–23.6  | 0                                 | Boyanova <sup>40</sup>              |
| France   | 1994–1999 | MonoC         | Ettest            | 150           | 21                                | 15.1–28.8 | 43                                | 35.3–51.7 | 0                                 | Kalach <sup>41</sup>                |
| Poland   | 1998–2000 | MonoC         | AD                | 98            | 23.5                              | 15.5–33.1 | ND                                |           | ND                                | Dzierzanowska-Fangrat <sup>42</sup> |
| Spain    | 1991–1999 | MonoC         | AD                | 246           | 21.1                              | 16.2–26.8 | 23                                | 18.0–29.0 | 0                                 | Lopez Brea <sup>43</sup>            |

Data from studies including more than 100 patients published during the last five years.

Clari<sup>R</sup>, clarithromycin resistant; Metro<sup>R</sup>, metronidazole resistant; Amoxi<sup>R</sup>, amoxicillin resistant.

DD, disk diffusion method; AD, agar dilution method; ND, not determined; 95% CI, 95% confidence interval; C, centre.

treatment.<sup>47</sup> No association with age was noted in adults in most studies or significant regional differences in a large country such as the USA. Interestingly, some studies compared macrolide consumption and the ensuing resistance in the corresponding countries over the years. For example, emergence of resistance to clarithromycin in Estonia in 1998 followed introduction of this drug in 1997.<sup>48</sup> In Japan, clarithromycin consumption multiplied by four between 1993 and 2000, and this led to a fourfold increase in clarithromycin resistance.<sup>31</sup> However, this was not case in the Netherlands; despite a threefold increase in clarithromycin prescriptions between 1993 and 1997, there was no significant increase in macrolide resistance.<sup>17</sup> This fact could be explained by the prudent use of antibiotics in this country. Indeed, when a comparison of antibiotic consumption was made in countries in the European Community, the Dutch had the lowest consumption.<sup>49</sup> Considering macrolide consumption evaluated in this last study in specific European regions, a perfect correlation could be made with the prevalence of clarithromycin resistance observed in the multicentre study of Glupczynski and colleagues.<sup>44</sup>

Although it is recognised that there is in vitro cross resistance between all macrolides, it is not clear whether all macrolides have the same potential to select resistant strains in vivo, depending on their diffusion in the gastric mucosa. Theoretically, based on in vitro data, when clarithromycin is present in the gastric mucosa at subinhibitory concentrations, it may select resistant strains. However, for other macrolides which may not even reach such a subinhibitory concentration, there is often little impact on the resistance selection process. With clarithromycin, in the case of treatment failure, emergence of resistance occurs in at least two thirds of strains.<sup>50</sup> This is not the case with azithromycin. In a French study, the rate of secondary resistance was only 23% after azithromycin therapy despite a high failure rate (62%).<sup>51</sup> The impact of erythromycin on selection of resistant strains may be more important. In Iran, the clarithromycin resistance rate is already 17% even though this drug has not been introduced in this country but erythromycin is used.<sup>28</sup> A similar situation was observed in France in 1993 (that is, an *H pylori* clarithromycin resistance rate of 8% was already noted probably due to the intense use of macrolides (erythromycin, josamycin, etc.) during the previous decade.<sup>52</sup>

Most studies did not mention any difference in prevalence according to the patient's disease status, with the exception

of two French studies and one in Germany. Firstly, in our prospective study on antimicrobial resistance, while the risk of harbouring a resistance strain for patients with non-ulcer dyspepsia (NUD) or other diseases was 1, it was only 0.08 (95% CI 0.011–0.66) for those with peptic ulcer disease.<sup>12</sup> Similar results were observed when risk factors for failure of *H pylori* therapy in all of the French clinical trials were studied.<sup>53</sup> In the subsample on which clarithromycin susceptibility was performed, strains from 5.6% of peptic ulcer patients were resistant compared with 16.7% of strains from NUD patients ( $p = 0.0005$ ). The same observation was made in Germany.<sup>54</sup> This could be related to the fact that virtually all of the peptic ulcer disease patients were infected with *cag* positive strains versus only half of the NUD patients, and these strains may be easier to eradicate,<sup>55</sup> possibly because their generation time is shorter or because they may be in closer contact with cells and therefore more accessible to the antibiotic. Another possibility is that NUD patients are simply greater consumers of antibiotics; in a Croatian study, for example, after multiple treatments of these two groups of patients, the prevalence of resistance was significantly higher in NUD patients.<sup>56</sup>

Another controversial point is the stability of the point mutation leading to resistance. Indeed, there are only a few positions, especially in domain V of the 23S rDNA, where mutations are found and where they change the spatial configuration of the ribosome, while mutations at other spots probably lead to non-viable organisms.<sup>57</sup> It was nevertheless possible to obtain some other mutants in vitro.<sup>58</sup> The key question lies in the impact of the mutations on the fitness of the bacterium. It is clear that if the mutation has a biological cost, it will not be maintained when selection pressure stops. In two studies, resistant mutants were followed after subculture in vitro as well as at different time points in vivo but resistance remained.<sup>59, 60</sup> However, others claim that clarithromycin resistance is not stable over the long term.<sup>61</sup>

The point mutation involved in resistance is interesting to consider. Its determination was made by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) or sequencing in 12 studies (table 3). The most frequent mutation was A2143G (69.8%) but its prevalence varied from 53% to 95%, followed by A2142G (11.7%) and A2142C (2.6%). This last mutation is probably underestimated because the relevant restriction enzyme to detect it was not used in most of the studies. However, one study reported

**Table 3** Prevalence of the different mutations associated with clarithromycin resistance in recent studies

| Country                    | No of strains tested | A2143G (No (%)) | A2142G (No (%)) | A2142C (No (%)) | T2717C (No (%)) | No detection (%) | Reference                           |
|----------------------------|----------------------|-----------------|-----------------|-----------------|-----------------|------------------|-------------------------------------|
| Germany (adults)           | 16                   | 9 (52.7)        | 3 (16)          |                 |                 | 4 (11)           | Wolle <sup>13</sup>                 |
| Italy                      | 12                   |                 |                 |                 | 7 (58.3)        | 5 (41.6)         | Fontana <sup>42</sup>               |
| Poland (children)          | 23                   | 16 (69.5)       | 4 (17.3)        | 2 (8.6)         |                 | 1 (4.3)          | Dzierzanowska-Fangraf <sup>42</sup> |
| Spain (children)           | 28                   | 23 (82.1)       | 2 (7.1)         |                 |                 | 3 (10.7)         | Alarcon <sup>63</sup>               |
| European multicentre study | 10                   | 7 (70)          | 2 (20)          |                 |                 | 1 (10)           | Mégraud <sup>19</sup>               |
| Brazil                     | 19                   | 14 (73.6)*      | 3 (18.7)        |                 |                 | 2 (10.5)         | Prazeres-Magalhaes <sup>27</sup>    |
| Hong Kong                  | 23                   | 22 (95.6)       | 1 (4.3)         |                 |                 |                  | Ling <sup>30</sup>                  |
| Iran                       | 20                   | 15 (75)         | 1 (5)           | 3 (15)          |                 | 1 (5)            | Mohammadi <sup>42</sup>             |
| Japan                      | 12                   | 11 (92)         |                 |                 |                 | 1 (8)            | Kato <sup>32</sup>                  |
| Japan                      | 9                    | 2 (22.2)        | 6 (66.6)        |                 |                 | 1 (11.1)         | Umegaki <sup>64</sup>               |
| Korea                      | 12                   | 8 (66.6)        |                 |                 |                 | 4 (33.3)**       | Kim <sup>65</sup>                   |
| Taiwan                     | 12                   | 10 (83.3)       | 1 (8.3)         |                 |                 | 1 (8.3)          | Yang <sup>66</sup>                  |
| Total                      | 196                  | 137 (69.8%)     | 23 (11.7%)      | 5 (2.6%)        | 7 (3.6%)        | 24 (12.2%)       |                                     |

\*Two strains also harboured the A2142G mutation.

\*\*These four strains had a T2182C mutation.

completely different results (that is, seven cases of a new mutation T2717C associated with a low MIC (1 mg/l) and five cases where no mutation was found). Such results warrant confirmation.

While there are differences in MICs between strains harbouring these different mutations, A2142G being the highest, the clinical relevance appears to be minimal.

#### Prevalence of *H pylori* resistance to amoxicillin

In all of the surveys reported in table 1, resistance to amoxicillin is either null or less than 1%, indicating that it is not yet a problem. Fortunately, plasmid borne beta lactamase resistance has never been encountered. In contrast, a strain has been found with an MIC of 8 mg/l due to a mutation in the *pbp-1A* gene<sup>67</sup>, probably selected following multiple cures of amoxicillin.<sup>68</sup> By culturing an amoxicillin susceptible strain with increasingly higher concentrations of amoxicillin, it was also possible to obtain strains with MICs of 4–8 mg/l which exhibited a decreased affinity for this drug.<sup>69</sup> Strains with high MICs obtained *in vivo*<sup>70</sup> or *in vitro*<sup>71</sup> have been used to transform susceptible strains. In all cases the authors obtained transformants with increased MICs but not higher than 0.5–2 mg/l. However, sequencing of *pbp-1A* in these different experiments<sup>67 70 71</sup> showed different mutations associated with resistance.

Other strains with decreased susceptibility (MIC 0.5 mg/l instead of 0.05 mg/l) are sometimes encountered. They have not been explored with regard to the mechanism involved but they may be the result of transformation. Their impact on *H pylori* eradication is also unknown. The existence of tolerant strains was raised in the past, and at that time a lack of a fourth PBP, PBP-D, was proposed as the mechanism.<sup>72</sup> Four of these strains have been studied recently. Transformants reached an MIC of 8 mg/l, which is still lower than that of clinical isolates. The suggestion was made that resistance was due to a mosaic block of PBP-1A which contained 10 amino acid changes.<sup>73</sup> Decreased susceptibility also observed for other antibiotics could not be clearly related to an efflux mechanism.

Very high resistance rates to amoxicillin have been reported in some prevalence studies.<sup>74 75</sup> However, these results must be interpreted with caution until the strains have been explored in depth.

#### Prevalence of *H pylori* resistance to tetracycline

Resistance to tetracycline is also very low, or even absent, in most countries. Cases have been reported in Spain (0.7%),<sup>19</sup> the UK (0.5%),<sup>21</sup> and Hong Kong (0.5%)<sup>30</sup> but also at a higher rate (5.3%) in Korea<sup>33</sup> (table 1).

With tetracycline, as well as with other antibiotics, resistance increases with the use of these drugs due to selection pressure. The resistance mechanism has been described as a change in three contiguous nucleotides in the 16S rRNA gene (AGA 926–928→TTC).<sup>76 77</sup>

*In vitro* experiments have shown that when mutations occur in only one or two of these nucleotides, resistance is at a low level (4 mg/l), which is clinically insignificant; only the triple mutation leads to stable and high resistance levels.<sup>78 79</sup> The need for a triple mutation may explain the rarity of tetracycline resistance.

#### Prevalence of *H pylori* resistance to metronidazole

The prevalence of *H pylori* resistance to metronidazole varies from 20% to 40% in Europe and the USA, with one exception

in Northern Italy.<sup>16</sup> It is well known that the prevalence is much higher in developing countries (50–80%), for example Mexico (76.3%)<sup>23</sup> (table 1). In contrast, the prevalence rate is quite low in Japan (9–12%).<sup>31 32</sup>

In the European multicentre study previously mentioned,<sup>44</sup> the global resistance rate to metronidazole was 33.1% (95% CI 7.5–58.9) with no significant difference between the North (33% (95% CI 7.1–69.2)) and South (40.8% (95% CI 27.3–54.3)) but a significantly lower prevalence in Central and Eastern parts (29.2% (95% CI 17.9–41.5)) ( $p < 0.01$ ). The global resistance rate shows a slight increase in comparison with that of a previous study carried out seven years earlier (1991) in Europe but where the centres were not exactly the same (27.5% (122/443) (95% CI 23.4–32.0)).<sup>80</sup>

The study by Boyanova and colleagues<sup>45</sup> in Eastern Europe reported a slightly higher prevalence using Etest (34.7% (95% CI 29.9–39.5)). The prevalence in Canada in the systematic review by Fallone was 18–22%.<sup>46</sup>

Emphasis should be made concerning the poor correlation between the different methods used to test *H pylori* resistance to metronidazole, with up to 10–20% discrepancies. Furthermore, reproducibility using a given method is also not good.<sup>20 24 81</sup> Nevertheless, although the exact prevalence rate obtained must be interpreted with caution, the trends of high, medium, or low resistance observed seem real.

In contrast with resistance mechanisms for other antibiotics, the resistance mechanism to metronidazole is not as straightforward.<sup>82 83</sup> Clearly, alterations of the *rdxA* gene are of prime importance but it has not been possible to identify a clear panel of point mutations which could explain the phenomenon. Moreover, other genes such as *fixA* also seem to be involved.<sup>84</sup>

When risk factors are studied, past use of metronidazole, which is common in tropical countries for parasitic diseases, is once more involved. In developed countries, most studies have reported a higher resistance rate in women than in men, probably due to the use of nitroimidazole drugs to treat gynaecological infections.<sup>44</sup> The use of nitroimidazole for dental infections may also add to selection pressure. In the USA there were no marked regional differences.

Interestingly, metronidazole resistant strains were found significantly more frequently among NUD patients from different ethnic backgrounds than in peptic ulcer patients (56.4% v 19.8%, respectively;  $p < 0.001$ ) in a recent study from Singapore while it was not mentioned in previous publications.<sup>36</sup>

#### Prevalence of *H pylori* resistance to fluoroquinolones

As in other bacteria, resistance of *H pylori* to fluoroquinolones is due to point mutations in the quinolone resistance determining regions of *gyrA*.<sup>85</sup> The prevalence of this resistance has been determined in only a limited number of studies. Only one country, Portugal, has reported a high resistance rate: 20.9% in strains isolated from 110 adult patients.<sup>18</sup> In the Netherlands, the rate was 4.7% (231 strains tested) with a drug, trovafloxacin, not yet introduced on the market, confirming cross resistance between the different molecules from this antibiotic group.<sup>17</sup> In France, a rate of 3.8% was reported between 1993 and 1999 on 655 strains<sup>52</sup> and was recently confirmed in another study (3.3%).<sup>86</sup> In five Eastern European countries the rate was also 3.9%.<sup>45</sup>

Again, resistance to fluoroquinolones mirrors the use of these drugs. Despite a high rate of resistance in adults in



**Table 4** *Helicobacter pylori* eradication with triple therapy (proton pump inhibitor-amoxicillin-clarithromycin) according to clarithromycin susceptibility or resistance

| Reference                   | Type of study  | Treatment        | Eradication rate  |                            |                          |
|-----------------------------|----------------|------------------|-------------------|----------------------------|--------------------------|
|                             |                |                  | Overall           | Clarithromycin susceptible | Clarithromycin resistant |
| Bago <sup>10</sup>          | Randomised     | OAC 1 week       | 84% (37/44)       | 89.7% (35/39)              | 40% (2/5)                |
| Bochenek <sup>54</sup>      | Randomised     | PAC 1 week       | 66.5% (137/206)   | 77.3% (130/182)            | 29.1% (7/24)             |
| Ducons <sup>95</sup>        | Successive     | LAC 1 week       | 79% (79/100)      | 85.5% (77/90)              | 20% (2/10)               |
| Hoshiya <sup>96</sup>       | Not randomised | OAC, LAC 1 week  | 77.5% (83/107)    | 83.1% (79/95)              | 33.3% (4/12)             |
| Kalach <sup>97†</sup>       | Successive     | OAC, LAC 1 week  | 81.9% (50/61)     | 100% (50/50)               | 0% (0/11)                |
| Katellaris <sup>98</sup>    | Randomised     | PAC 1 week       | 80.4% (37/46)     | 86% (36/42)                | 25% (1/4)                |
| Kawabata <sup>99</sup>      | Randomised     | LAC, RAC 1 week  | 78% (135/173)     | 85.5% (130/152)            | 23.8% (5/21)             |
| Kihira <sup>100</sup>       | Randomised     | RAC              | 92.6% (79/85)     | 96.3% (79/82)              | 0% (0/3)                 |
| Laine <sup>25</sup>         | Randomised     | OAC              | 85.8% (91/106)    | 94.6% (88/93)              | 23% (3/13)               |
| Lamouliatte <sup>101</sup>  | Randomised     | PAC 1 week       | 81.1% (82/101)    | 86% (82/95)                | 0% (0/6)                 |
| Lamouliatte <sup>102*</sup> | Randomised     | OAC 1 or 2 weeks | 48.3% (57/118)    | 80% (48/60)                | 15.5% (9/58)             |
| Lehman <sup>103</sup>       | Randomised     | LAC 2 weeks      | 72% (23/32)       | 87% (23/29)                | 0% (0/3)                 |
| Lind <sup>104</sup>         | Randomised     | OAC 1 week       | 95.7% (113/118)   | 97% (111/116)              | 100% (2/2)               |
| McMahon <sup>105</sup>      | Not randomised | LAC 2 weeks      | 71.6% (38/53)     | 87.5% (35/40)              | 23% (3/13)               |
| Miki <sup>106</sup>         | Randomised     | OAC, RAC 1 week  | 87% (120/138)     | 97.5% (119/122)            | 6.3% (1/16)              |
| Murakami <sup>107</sup>     | Randomised     | RAC, LAC 1 week  | 85.3% (227/266)   | 94% (226/241)              | 4% (1/25)                |
| Peitz <sup>108*</sup>       | Randomised     | OAC 1 week       | 48.5% (17/35)     | 83% (10/12)                | 30% (7/23)               |
| Pilotto <sup>109</sup>      | Randomised     | PAC 1 week       | 85% (34/40)       | 87% (33/38)                | 50% (1/2)                |
| Poon <sup>110</sup>         | Randomised     | LAC 1 week       | 84% (37/44)       | 95% (37/39)                | 0% (0/5)                 |
| Tankovic <sup>111</sup>     | Successive     | OAC 1 week       | 67.6% (69/102)    | 79% (67/85)                | 12% (2/17)               |
| Total                       |                |                  | 78.2% (1545/1975) | 87.8% (1495/1702)          | 18.3% (50/273)           |

\*Second line treatment.  
†Children.  
O, omeprazole; L, lansoprazole; P, pantoprazole; C, clarithromycin; M, metronidazole; R, ranitidine; A, amoxicillin; PPI, proton pump inhibitor.

Portugal, children who were not treated with quinolones did not harbour any resistant strains.<sup>18</sup>

This also indicates the high risk of selection of resistant strains which may jeopardise the new promising fluoroquinolone based rescue therapies (proton pump inhibitor-amoxicillin-levofloxacin or moxifloxacin).

#### Prevalence of *H pylori* resistance to rifabutin

The prevalence of *H pylori* resistance to this group of antibiotics is not known but is probably extremely low as these drugs, until recently, were used only in a limited number of patients to treat mycobacterial infections. For example, Heep *et al* did not find a single resistant strain from 81 tested in 1999<sup>87</sup> in Germany and nor did Fujimura *et al* among 52 strains in Japan.<sup>88</sup> However, the use of these drugs could also lead to the emergence of resistant strains, as was observed in one case of treatment failure.<sup>89</sup> Again, resistance

is due to point mutations in the *rpoB* gene, as for other bacteria, and concerns all rifamycin drugs.<sup>90-91</sup>

#### Double resistant strains

As clarithromycin and metronidazole are the antibiotics most frequently used with amoxicillin, it was interesting to see if both resistances were evenly distributed. Most of the studies presented in tables 1 and 2 give an indication of the prevalence of these double resistant strains. It was found that they were twice as frequent as expected. However, given their proportion among the total number of strains, their prevalence is still low in Europe (0.8–9.1%) and in Asia (2–3%), and much higher in developing countries such as Mexico (18%). The situation is different after failure of a therapy using both clarithromycin and metronidazole, and up to 50% of strains may then harbour double resistance.<sup>50</sup>

**Table 5** *Helicobacter pylori* eradication with triple therapy (proton pump inhibitor-clarithromycin-metronidazole) according to susceptibility or resistance to both antibiotics

| Reference                  | Type of study | Type of treatment | Overall         | Eradication rate          |                            |                          |                            |
|----------------------------|---------------|-------------------|-----------------|---------------------------|----------------------------|--------------------------|----------------------------|
|                            |               |                   |                 | Metronidazole susceptible |                            | Metronidazole resistant  |                            |
|                            |               |                   |                 | Clarithromycin resistant  | Clarithromycin susceptible | Clarithromycin resistant | Clarithromycin susceptible |
| Bazzoli <sup>112</sup>     | Randomised    | OCT               | 91.3% (21/23)   | 0                         | 18/18                      | 0/1                      | 3/4                        |
| Damman <sup>14</sup>       | Randomised    | PCM               | 85.1% (160/188) | 0/3                       | 123/125                    | 0/1                      | 37/59                      |
| Ellenrieder <sup>113</sup> | Successive    | PCM               | 92.8% (78/84)   | 2/3                       | 63/67                      | 0                        | 13/14                      |
| Hurenkamp <sup>114</sup>   | Randomised    | OCM               | 100% (74/74)    | 1/1                       | 57/57                      | 0                        | 16/16                      |
| Lind <sup>25</sup>         | Randomised    | OCM               | 89.4% (102/114) | 4/6                       | 73/75                      | 0                        | 25/33                      |
| Pilotto <sup>109</sup>     | Randomised    | PCM               | 82.8% (29/35)   | 2/3                       | 24/25                      | 0                        | 3/7                        |
| Poon <sup>110</sup>        | Randomised    | LCM               | 73.5% (25/34)   | 0/2                       | 15/16                      | 0/3                      | 10/13                      |
| Savarino <sup>115</sup>    | Randomised    | OCM               | 73.1% (30/41)   | 2/4                       | 18/20                      | 0/2                      | 10/15                      |
| Total                      |               |                   |                 | 50.0% (11/22)             | 97.0% (391/403)            | 0/7                      | 72.6% (117/161)            |

O, omeprazole; L, lansoprazole; P, pantoprazole; C, clarithromycin; M, metronidazole; T, tinidazole.

**Table 6** *Helicobacter pylori* eradication with triple therapy (ranitidine bismuth citrate-clarithromycin-metronidazole) according to susceptibility or resistance to both antibiotics

| Reference               | Type of study | Type of treatment | Overall       | Eradication rate          |                            |                          |                            |
|-------------------------|---------------|-------------------|---------------|---------------------------|----------------------------|--------------------------|----------------------------|
|                         |               |                   |               | Metronidazole susceptible |                            | Metronidazole resistant  |                            |
|                         |               |                   |               | Clarithromycin resistant  | Clarithromycin susceptible | Clarithromycin resistant | Clarithromycin susceptible |
| Bardhan <sup>116</sup>  | Randomised    | RBC-CM            | 97.6% (41/42) | 0                         | 100% (32/32)               | 0/1                      | 100% (9/9)                 |
| Savarino <sup>115</sup> | Randomised    | RBC-CM            | 97.2% (35/36) | 2/2                       | 100% (17/17)               | 66% (2/3)                | 100% (14/14)               |
| Sung <sup>117</sup>     | Randomised    | RBC-CM            | 92.8% (52/56) | 1/1                       | 91.3% (21/23)              | 0/1                      | 96.7% 30/31                |
| Total                   |               |                   |               | 100% (3/3)                | 97.2% (70/72)              | 40% (2/5)                | 98.1% (53/54)              |

RBC, ranitidine bismuth citrate; C, clarithromycin; M, metronidazole.

## CONSEQUENCES OF *HELICOBACTER PYLORI* RESISTANCE TO ANTIBIOTICS

Antibiotic resistance is important if it leads to treatment failure. We reviewed the clinical relevance in 1998 at a time when data on susceptibility testing were scarce.<sup>92</sup> One year later a systematic review was published based on data from 16 of 172 arms where proton pump inhibitor-clarithromycin-amoxicillin therapy was given, and for which susceptibility testing was performed.<sup>93</sup> Table 4 is not a systematic review but presents data from 20 recent studies (1999–2003) and 1975 patients receiving the same treatment where susceptibility testing was performed. Unfortunately, these studies still represent a low proportion of the studies carried out (for example, 436 of 2751 patients among the French studies<sup>93</sup>) and sometimes the data are not presented in an adequate manner. A major difference in eradication rates was found: 87.8% when strains were clarithromycin susceptible compared with 18.3% when strains were clarithromycin resistant. The Mantel-Haenszel pooled odds ratio (OR) was highly significant (OR 24.5 (95% CI 17.2–35.0),  $p < 0.001$ ). It was 22.5 using the fixed effect model and 28.7 with the random effect model.

This 70% decrease in clinical success is higher than the 53% decrease reported in the meta-analysis by Houben and colleagues<sup>93</sup> and confirms the high clinical relevance of clarithromycin resistance. Fortunately, the prevalence of clarithromycin resistance is still low in many places, as shown in table 1, but deserves monitoring at least in some centres.

Conversely, these results indicate the high success rate of this treatment (87.8%) when strains are susceptible, regardless of the proton pump inhibitor, dosage of the different drugs, and duration of the treatment.

Data from eight studies where a nitroimidazole compound was administered with clarithromycin instead of amoxicillin were also reviewed (table 5). When considering nitroimidazole resistance alone, there was a 25% decrease in the success rate compared with nitroimidazole susceptible strains (72.6%  $v$  97%), which is identical to that observed by Houben and colleagues<sup>93</sup> indicating that nitroimidazole resistance is less clinically relevant than clarithromycin resistance. The Mantel-Haenszel pooled OR was 11.3 (95% CI 5.7–22.3;  $p < 0.001$ ). It was 10.4 using the fixed effect model and 9.8 with the random effect model.

Furthermore, in the context of this treatment, clarithromycin resistance seems to lead less often to treatment failure (50%  $v$  18.3%). A small number of strains were resistant to both antibiotics and none could be eradicated, reinforcing the fear of using this combination as a first line treatment because resistance to both drugs may be selected.

Few studies have used ranitidine bismuth citrate (RBC) instead of a proton pump inhibitor but data available indicate better efficacy of this combination, especially on metronidazole resistant strains (table 6). This result may be due to synergism between RBC and antibiotics.<sup>118</sup> Such a synergy may also exist when a bismuth based quadruple therapy is used.<sup>26 119</sup>

The combination of proton pump inhibitor-amoxicillin-metronidazole has also been used in six trials (table 7). For metronidazole susceptible strains, the eradication rate was similar to the association of amoxicillin-clarithromycin (susceptible strains: 89.4%  $v$  87.8%) which is inferior to the combination with clarithromycin (when strains are also susceptible: 89.4%  $v$  97%; ( $p < 0.001$ ). A 25% drop in efficacy was also observed when strains were metronidazole resistant.

Interestingly, some authors compared a susceptibility testing strategy with an empirical treatment (table 8).

**Table 7** *Helicobacter pylori* eradication with triple therapy (proton pump inhibitor-amoxicillin-metronidazole) according to susceptibility or resistance to metronidazole

| Reference                   | Type of treatment | Eradication rate |                           |                         |
|-----------------------------|-------------------|------------------|---------------------------|-------------------------|
|                             |                   | Overall          | Metronidazole susceptible | Metronidazole resistant |
| Bardhan <sup>120</sup>      | OAM 1 week        | 81.5% (274/336)  | 87% (233/266)             | 57% (41/70)             |
| Bayerdorffer <sup>121</sup> | OAM 1 week        | 88% (96/109)     | 91% (81/89)               | 75% (15/20)             |
| Isomoto <sup>122*</sup>     | RAM 2 weeks       | 91.6% (33/36)    | 93% (27/29)               | 86% (6/7)               |
| Lamouliatte <sup>102*</sup> | OAM 2 weeks       | 69.8% (67/96)    | 81% (38/47)               | 59% (29/49)             |
| Murakami <sup>123*</sup>    | RAM 1 week        | 92.9% (79/85)    | 96.8% (61/63)             | 81.8% (18/22)           |
| Pilotto <sup>109</sup>      | PAM 1 week        | 85.2% (29/34)    | 96% (24/25)               | 56% (5/9)               |
| Total                       |                   | 83% (578/696)    | 89.4% (464/519)           | 64.4% (114/177)         |

\*Second line *H pylori* eradication treatment.

O, omeprazole; P, pantoprazole; R, rabeprazole; M, metronidazole; A, amoxicillin.

**Table 8** Comparison of an empirical treatment with a susceptibility testing strategy to eradicate *Helicobacter pylori*

| Reference                    | Treatment   | Empirical treatment group |               |      | Susceptibility testing group |               |      |
|------------------------------|-------------|---------------------------|---------------|------|------------------------------|---------------|------|
|                              |             | n                         | % eradication |      | n                            | % eradication |      |
|                              |             |                           | ITT           | PP   |                              | ITT           | PP   |
| Lamouliatte <sup>102,†</sup> | OAM 2 weeks | 57                        | 63.2          | 72.1 | 113                          | 74.3          | 78.3 |
| Miwa <sup>124</sup>          | LAM         | 39                        | 92.4          | 94.7 | 38                           | 81.6          | 83.3 |
| Neri <sup>125</sup>          | OCA RBC-CT  | 116                       | 67            |      | 116                          | 76*           |      |
| Romano <sup>126</sup>        | OMC         | 39                        | 79.5          | 77.5 | 40                           | 95            | 97.4 |
| Toracchio <sup>127</sup>     | OMC         | 56                        | 75            | 81   | 53                           | 91            | 98   |

\*Eradication rate was 64% using OCA and 87% using RBC-CT.

†Second line treatment.

O, omeprazole; A, amoxicillin; L, lansoprazole; M, metronidazole; C, clarithromycin; T, tinidazole; RBC, ranitidine bismuth citrate.

ITT, intention to treat; PP, per protocol.

There was a marked advantage in using the susceptibility testing strategy in two studies. Indeed, the strategy depends very much on the treatment used. For Neri *et al*, an empirical treatment using RBC was the most efficient.<sup>125</sup>

### ADVANCES IN TESTING

Overwhelming evidence indicates that antibiotic resistance in *H pylori* is essentially due to chromosomal mutations. An important consequence of this finding is that transmission of resistance essentially occurs vertically from the organism in which the mutation appears to its descendants, and therefore a progressive increase in resistance is observed according to selection pressure rather than a rapid outbreak-like spread when resistance in plasmid borne. However, genetic exchanges seem to be numerous between different strains of *H pylori* and therefore the possibility of transmission of resistance does exist. This opportunity is probably on the decrease in our Western societies given that gastric infections are now essentially due to a unique strain. In vitro studies have shown, for example, that metronidazole resistance could be transmitted by transformation.<sup>128</sup>

The genes involved in mutations have been readily identified and presented earlier in this article. They are summarised in table 9. In most cases there is a limited number of point mutations which allows the development of molecular methods to be used for their detection.

The usual methods of phenotypic detection of resistance are still widely used. The recent European standardisation<sup>81</sup> has led to recommendation of a similar protocol to that of the US NCCLS. Given the important difference observed in MICs between clarithromycin susceptible and resistance strains, the simple and cheap disk diffusion method has been validated. The best results were obtained using an erythromycin disk.<sup>129</sup> New methods have been developed. These

**Table 9** Genes involved in point mutations or other genetic events leading to antibiotic resistance in *Helicobacter pylori*

| Antibiotic group | Gene involved             |
|------------------|---------------------------|
| Macrolides       | 23S <i>rrm</i>            |
| Metronidazole    | <i>rdxA</i> , <i>frxA</i> |
| Quinolones       | <i>gyrA</i>               |
| Rifamycins       | <i>rpoB</i>               |
| Amoxicillin      | <i>pbp-1A</i>             |
| Tetracycline     | 16S <i>rrm</i>            |

methods are essentially molecular methods given that point mutations are the unique mechanism of resistance in *H pylori*, and PCR based methods are most often used. These methods have been extensively reviewed in 2002 in this journal.<sup>130</sup> However, for metronidazole the complexity of the phenomenon does not allow this approach and a new phenotypic method has been proposed.

### Detection of clarithromycin resistance

Among the numerous methods described (table 10), the most promising for the future is application of real time PCR. The first apparatus, the Lightcycler, was designed to perform quantitative PCR<sup>146</sup> but now has a major application in detecting point mutations. A technology named fluorescence resonance energy transfer (FRET) can be applied. In the first article by Gibson and colleagues<sup>140</sup> in 1999, a DNA double strand specific fluorophor SYBR Green 1 and a second fluor dye Cy5 on a probe were used to test *H pylori* strains. This method was then applied to gastric biopsies.<sup>141</sup> Later, another approach was used: in addition to the specific primers targeting 23S rDNA, two probes were designed: (1) a sensor probe 5' labelled with LC-Red 640 and 3' phosphorylated, which hybridises with the region containing the mutation site and (2) an anchor probe 3' labelled with fluorescein which hybridises three bases upstream from the former. When the anchor probe is excited, an energy transfer occurs to the sensor probe and a signal is emitted. After amplification, a melting step is performed which leads to different melting points for the wild-type and mutants.<sup>142-144</sup> This method allows detection of *H pylori* and determination of its clarithromycin susceptibility directly from biopsy specimens

**Table 10** Molecular methods for *Helicobacter pylori* testing of clarithromycin resistance

|  |
|--|
| Based on amplification of 23S rRNA gene  |
| - Sequencing   |
| - RFLP (restriction fragment length polymorphism) <sup>131 132</sup>               |
| - OLA (oligonucleotide ligation assay) <sup>133</sup>                              |
| - DEIA (DNA enzyme immunoassay) <sup>134 135</sup>                                 |
| - PHFA (preferential homoduplex formation assay) <sup>136</sup>                    |
| - INNO-LiPA (line probe assay) <sup>137</sup>                                      |
| - Mismatch PCR <sup>138</sup>  |
| - DG-DGGE (double gradient-denaturing gradient gel electrophoresis) <sup>139</sup> |
| - FRET (fluorescence resonance energy transfer) <sup>140-144</sup>                 |
| Based on hybridisation   |
| - FISH assay (fluorescence in situ hybridisation assay) <sup>145</sup>             |

in one reaction which takes two hours and limits the possibility of contamination with PCR products as the entire reaction occurs in the same tube. It has proven to be highly sensitive and specific. However, because there are not many 23S rRNA sequences from other helicobacters available in data banks, and because other helicobacters are seldom found, specificity among uncommon *Helicobacter* species has not been extensively tested.

A recent development is the application of this technology, not to gastric biopsy samples, but to stool samples, which offers a non-invasive method of performing susceptibility testing. Preliminary results have been presented<sup>147</sup> and look promising.

Additional progress for those using the more traditional PCR-RFLP method was the description of a new restriction enzyme allowing detection of the A2142C mutation.<sup>148</sup>

The possibility of detecting clarithromycin resistance without performing PCR also exists, by fluorescence in situ hybridisation (FISH). This method has been applied to the detection of *H pylori* and its clarithromycin resistance by Trebesius and colleagues.<sup>145</sup> It consists of an rRNA based whole cell in situ hybridisation using a set of fluorescent labelled oligonucleotide probes. Labelling of intact single bacteria is monitored by fluorescence microscopy. This method allows detection of *H pylori* with a 16S rRNA probe labelled with the fluorochrome Cy3 (red) and of resistant mutants with a 23S rRNA probe labelled with fluorescein (green) simultaneously. This method proved to be sensitive and specific compared with standard methods of culture and susceptibility testing. No discrepant result was noted for 45 cases.<sup>149</sup> In another study, there were 11 discrepant results among 69 cases. These cases corresponded to mixed infections with susceptible and resistant strains.<sup>150</sup> This method has the advantage of being independent of nucleic acid preparations, it is not prone to inhibition such as PCR, and is quick. It also allows visualisation of the bacteria, including coccoidal forms, and can be performed on paraffin embedded biopsy samples.<sup>151</sup> A limitation could be the observer dependent result, and sometimes difficulty in reading.

All of the techniques described highlight the fact that mixed infections between clarithromycin susceptible and resistant bacteria are frequent. In a study performed in our laboratory, multiple genotypes were found in 21.1% of cases.<sup>143</sup> Usually the essential part of the bacterial population corresponds to the susceptible genotype, indicating that resistance occurs spontaneously, remains at a low concentration, and is subsequently selected by administration of the drug.

### Detection of metronidazole resistance

An interesting approach based on the detection of the RdxA protein by immunoblotting with specific rabbit anti-RdxA antibodies has been proposed.<sup>152</sup> A 24 kDa immunoreactive band corresponding to the RdxA protein is observed in all metronidazole susceptible isolates while it is not found in most metronidazole resistant isolates. However, this band was present in approximately 10% of metronidazole resistant isolates in the two studies performed. Complementary experiments proved that these isolates contained mutations associated with inactivation of the *rdxA* gene.<sup>153</sup>

Despite this limit, this new approach looks promising, given the high discrepancies observed when using different phenotypic methods and even the lack of reproducibility with a given method.

### Detection of other resistances

Although the primary material for developing molecular tests for other antibiotics (tetracycline, quinolones, rifamycin) do exist, these tests have not yet been developed, probably because of the low frequency of resistant strains. Better knowledge of the *pbp1* gene domain where mutations occur<sup>154</sup> should help in developing a molecular method for the rare amoxicillin resistant *H pylori*.

### REFERENCES

- 1 European Helicobacter pylori Study Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht consensus report. *Gut* 1997;**41**:8–13.
- 2 The report of the Digestive Health Initiative International Update on Helicobacter pylori. *Gastroenterology* 1997;**113**:S4–5.
- 3 Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. *J Gastroenterol Hepatol* 1998;**13**:1–12.
- 4 Hunt RH, Fallone CA, Thomson ABR. Canadian Helicobacter pylori Consensus Conference update: infections in adults. *Can J Gastroenterol* 1999;**13**:213–17.
- 5 Coelho LG, Leon-Barua R, Quigley EMM, et al. Latin-American consensus conference on Helicobacter pylori infection. *Am J Gastroenterol* 2000;**95**:2688–91.
- 6 Malfertheiner P, Mégraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection—The Maastricht 2-2000 Consensus Report. *Aliment Pharmacol Ther* 2002;**16**:167–80.
- 7 Mégraud F, Lamouliatte H. The treatment of refractory Helicobacter pylori infection. *Aliment Pharmacol Ther* 2003;**17**:1333–43.
- 8 Mégraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. *Gastroenterology* 1998;**115**:1278–82.
- 9 Mégraud F, Hazell S, Glupczynski Y. Antibiotic susceptibility and resistance. In: Mobley HLT, Mendz GL, Hazell SL, eds. *Helicobacter pylori: physiology and genetics*. Washington, DC: ASM Press, 2001:511–30.
- 10 Boyanova L, Spassova Z, Krastev Z, et al. Characteristics and trends in macrolide resistance among Helicobacter pylori strains isolated in Bulgaria over four years. *Diagn Microbiol Infect Dis* 1999;**34**:309–13.
- 11 Bago J, Halle ZB, Strinic D, et al. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in *H. pylori* eradication—a randomised controlled trial. *Wien Klin Wochenschr* 2002;**114**:448–53.
- 12 Mégraud F. Surveillance de la résistance de Helicobacter pylori aux antibiotiques. In: *Surveillance nationale des maladies infectieuses 1998–2000*. St Maurice, France: Institut de Veille Sanitaire, 2003:327–9.
- 13 Wolle K, Leodolter A, Malfertheiner P, et al. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. *J Med Microbiol* 2002;**51**:705–9.
- 14 Dammann HG, Folsch UR, Hahn EG, et al. Eradication of *H. pylori* with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration. *Helicobacter*, 2000;**5**:41–51.
- 15 Toracchio S, Marzio L. Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998–2000. *Dig Liver Dis* 2003;**35**:541–5.
- 16 Pilotto A, Rassu M, Leandro G, et al. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. *Dig Liver Dis* 2000;**32**:763–8.
- 17 Debets-Ossenkopp YJ, Herscheid A, Pot RGJ, et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and trovafloxacin in The Netherlands. *J Antimicrob Chemother* 1999;**43**:511–15.
- 18 Cabrita J, Oleastro M, Matos R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990–1999). *J Antimicrob Chemother* 2000;**46**:1029–31.
- 19 Cuchi Burgos E, Forne Boldera M, Quintana Riera S, et al. Evolution of the sensitivity of 235 strains of Helicobacter pylori from 1995 to 1998 and impact of antibiotic treatment *Enferm Infecc Microbiol Clin* 2002;**20**:157–60.
- 20 Mégraud F, Lehn N, Lind T, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicentre trial: the MACH 2 study. *Antimicrob Agents Chemother* 1999;**43**:2747–52.
- 21 Parsons HK, Carter MJ, Sanders DS, et al. Helicobacter pylori antimicrobial resistance in the United Kingdom: the effect of age, sex and socio-economic status. *Aliment Pharmacol Ther* 2001;**15**:1473–8.
- 22 Teare L, Peters T, Saverymutter S, et al. Antibiotic resistance in Helicobacter pylori. *Lancet* 1999;**353**:242.
- 23 Torres J, Camorlinga-Ponce M, Perez-Perez G, et al. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. *J Clin Microbiol* 2001;**39**:2677–80.
- 24 Osato MS, Reddy R, Reddy SG, et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. *Arch Intern Med* 2001;**161**:1217–20.
- 25 Laine L, Fennerty MB, Osato M, et al. Esomeprazole-based Helicobacter pylori eradication therapy and the effect of antibiotic resistance: results of three US multicentre, double-blind trials. *Am J Gastroenterol* 2000;**95**:3393–8.



- 26 **Laine L**, Hunt R, El-Zimaity H, *et al*. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of *Helicobacter pylori* in duodenal ulcer patients: a prospective, randomized, multicentre, North American trial. *Am J Gastroenterol* 2003;**98**:562-7.
- 27 **Prazeres Magalhaes P**, De Magalhaes Queiroz DM, Campos Barbosa DV, *et al*. *Helicobacter pylori* primary resistance to metronidazole and clarithromycin in Brazil. *Antimicrob Agents Chemother* 2002;**46**:2021-3.
- 28 **Mohammadi M**, Doroud D, Massarrat S, *et al*. Clarithromycin resistance in Iranian *H. pylori* strains before introduction of clarithromycin. *Helicobacter* 2003;**8**:79-80.
- 29 **Samra Z**, Shmueli H, Niv Y, *et al*. Resistance of *Helicobacter pylori* isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicillin and cefixime. *J Antimicrob Chemother* 2002;**49**:1023-6.
- 30 **Ling TKW**, Leung WK, Lee CC, *et al*. The antimicrobial susceptibility of *Helicobacter pylori* in Hong Kong (1997-2001). *Helicobacter* 2002;**7**:327-9.
- 31 **Perez Aldana L**, Kato M, Nakagawa S, *et al*. The relationship between consumption of antimicrobial agents and the prevalence of primary *Helicobacter pylori* resistance. *Helicobacter* 2002;**7**:306-9.
- 32 **Kato M**, Yamooka Y, Kim JJ, *et al*. Regional differences in metronidazole resistance and increasing clarithromycin resistance among *Helicobacter pylori* isolates from Japan. *Antimicrob Agents Chemother* 2000;**44**:2214-16.
- 33 **Kim JJ**, Reddy R, Lee M, *et al*. Analysis of metronidazole, clarithromycin and tetracycline resistance of *Helicobacter pylori* isolates from Korea. *J Antimicrob Chemother* 2001;**47**:459-61.
- 34 **Eun CS**, Han DS, Park JY, *et al*. Changing pattern of antimicrobial resistance of *Helicobacter pylori* in Korean patients with peptic ulcer diseases. *J Gastroenterol* 2003;**38**:436-41.
- 35 **Teo EK**, Fock KM, Ng TM, *et al*. Metronidazole-resistant *Helicobacter pylori* in an urban Asian population. *J Gastroenterol Hepatol* 2000;**15**:494-7.
- 36 **Lui SY**, Yeoh KG, Ho B. Metronidazole-resistant *Helicobacter pylori* is more prevalent in patients with nonulcer dyspepsia than in peptic ulcer patients in a multiethnic Asian population. *J Clin Microbiol* 2003;**41**:5011-14.
- 37 **Fraser AG**, Moore L, Hackett M, *et al*. *Helicobacter pylori* treatment and antibiotic susceptibility: results of a five-year audit. *Aust N Z J Med* 1999;**29**:512-16.
- 38 **Crone J**, Granditsch G, Huber WD, *et al*. *Helicobacter pylori* in children and adolescents: increase of primary clarithromycin resistance, 1997-2000. *J Pediatr Gastroenterol Nutr* 2003;**36**:368-71.
- 39 **Bontems P**, Devaster JM, Corvaglia L, *et al*. Twelve year observation of primary and secondary antibiotic-resistant *Helicobacter pylori* strains in children. *Pediatr Infect Dis J* 2001;**20**:1033-8.
- 40 **Boyanova L**, Koumanova R, Gergova G, *et al*. Prevalence of resistant *Helicobacter pylori* isolates in Bulgarian children. *J Med Microbiol* 2002;**51**:786-90.
- 41 **Kalach N**, Gergeret M, Benhamou PH, *et al*. High levels of resistance to metronidazole and clarithromycin in *Helicobacter pylori* strains in children. *J Clin Microbiol* 2001;**39**:394-7.
- 42 **Dzierzanowska-Fangrat K**, Rozynek E, Jozwiak P, *et al*. Primary resistance to clarithromycin in clinical strains of *Helicobacter pylori* isolated from children in Poland. *Int J Antimicrob Agents* 2001;**18**:387-90.
- 43 **Lopez-Brea M**, Martinez MJ, Domingo D, *et al*. A 9 year study of clarithromycin and metronidazole resistance in *Helicobacter pylori* from Spanish children. *J Antimicrob Chemother* 2001;**48**:295-7.
- 44 **Glupczynski Y**, Mégraud F, Lopez-Brea M, *et al*. European multicenter survey of *in vitro* antimicrobial resistance in *Helicobacter pylori*. *Eur J Clin Microbiol Infect Dis* 2000;**11**:820-3.
- 45 **Boyanova L**, Mentis A, Gubina M, *et al*. The status of antimicrobial resistance of *Helicobacter pylori* in eastern Europe. *Clin Microbiol Infect* 2002;**8**:388-96.
- 46 **Fallone CA**. Epidemiology of the antibiotic resistance of *Helicobacter pylori* in Canada. *Can J Gastroenterol* 2000;**14**:879-82.
- 47 **Taneike I**, Goshi S, Tamura Y, *et al*. Emergence of clarithromycin-resistant *Helicobacter pylori* (CRHP) with a high prevalence in children compared with their parents. *Helicobacter* 2002;**7**:297-305.
- 48 **Loivukene K**, Maaroos HI, Kolk H, *et al*. Prevalence of antibiotic resistance of *Helicobacter pylori* isolates in Estonia during 1995-2000 in comparison to the consumption of antibiotics used in treatment regimens. *Clin Microbiol Infect* 2002;**8**:598-603.
- 49 **Cars O**, Mälsted S, Melander Z. Variation in antibiotic use in the European Union. *Lancet* 2001;**357**:1851-3.
- 50 **Heep M**, Kist M, Strobel S, *et al*. Secondary resistance among 554 isolates of *Helicobacter pylori* after failure of therapy. *Eur J Clin Microbiol Infect Dis* 2000;**19**:538-41.
- 51 **Laurent J**, Mégraud F, Fléjou JF, *et al*. A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of *Helicobacter pylori* in patients with non-ulcer dyspepsia. *Aliment Pharmacol Ther* 2001;**15**:1787-93.
- 52 **Birac C**, Bouchard S, Camou C, *et al*. Six year follow-up of resistance to antibiotics of *Helicobacter pylori* in Bordeaux, France. *Gut* 1999;**45**(suppl 3):A107.
- 53 **Broutet N**, Tchamgoue S, Pereira E, *et al*. Risk factors for failure of *Helicobacter pylori* therapy-results of an individual data analysis of 2751 patients. *Aliment Pharmacol Ther* 2003;**17**:99-109.
- 54 **Kist M**, Glocker E, Wolf B, *et al*. ResiNet-A nationwide German sentinel study on development and risk factors of antimicrobial resistance in *Helicobacter pylori*. *Helicobacter* 2003;**8**:465.
- 55 **Broutet N**, Marais A, Lamouliatte H de Mascarel A, *et al*. *cagA* status and eradication treatment outcome of anti-*Helicobacter pylori* triple therapies in non-ulcer dyspeptic patients. *J Clin Microbiol* 2001;**39**:1319-22.
- 56 **Katicic M**, Ticak M, Kalenic S, *et al*. Sensitivity of *Helicobacter pylori* to metronidazole and macrolides in GERD/NUD and peptic ulcer patients with *Helicobacter pylori* eradication failure. *Helicobacter* 2003;**8**:471.
- 57 **Mégraud F**. *Helicobacter pylori* and macrolides. In: Schönfeld W, Kirst HA, eds. *Macrolide antibiotics*. Berlin: Birkhäuser Verlag, 2002:243-60.
- 58 **Debets-Ossenkopp YJ**, Brinkman AB, Kuipers EJ, *et al*. Explaining the bias in the 23S rRNA gene mutations associated with clarithromycin resistance in clinical isolates of *Helicobacter pylori*. *Antimicrob Agents Chemother* 1998;**42**:2749-51.
- 59 **Mégraud F**, Camou-Juncas C, Occhialini A, *et al*. *Helicobacter pylori* resistance levels to clarithromycin remain stable. *Gastroenterology* 1996;**110**:A192.
- 60 **Hulten K**, Gibreel A, Sköld O, *et al*. Macrolide resistance in *Helicobacter pylori*: Mechanism and stability in strains from clarithromycin-treated patients. *Antimicrob Agents Chemother* 1997;**41**:2550-3.
- 61 **Xia H**, Buckley M, Keane CT, *et al*. Clarithromycin resistance in *Helicobacter pylori*: prevalence in untreated dyspeptic patients and stability *in vitro*. *J Antimicrob Chemother* 1996;**37**:473-81.
- 62 **Fontana C**, Favaro M, Minelli S, *et al*. New site of modification of 23S rRNA associated with clarithromycin resistance of *Helicobacter pylori* clinical isolates. *Antimicrob Agents Chemother* 2002;**46**:3765-9.
- 63 **Alarcon T**, Vega AE, Domingo D, *et al*. Clarithromycin resistance among *Helicobacter pylori* strains isolated from children: prevalence and study of mechanism of resistance by PCR-restriction fragment length polymorphism analysis. *J Clin Microbiol* 2003;**41**:486-99.
- 64 **Umegaki N**, Shimoyama T, Nishiya D, *et al*. Clarithromycin-resistance and point mutations in the 23S rRNA gene in *Helicobacter pylori* isolates from Japan. *J Gastroenterol Hepatol* 2000;**15**:906-9.
- 65 **Kim KS**, Kang JO, Eun CS, *et al*. Mutations in the 23S rRNA gene of *Helicobacter pylori* associated with clarithromycin resistance. *J Korean Med Sci* 2002;**17**:599-603.
- 66 **Yang YJ**, Yang JC, Jeng YM, *et al*. Prevalence and rapid identification of clarithromycin-resistant *Helicobacter pylori* isolates in children. *Pediatr Infect Dis J* 2001;**20**:662-6.
- 67 **Gerrits MM**, Schuijffel D, van Zwet AA, *et al*. Alterations in penicillin-binding protein 1A confer resistance to  $\beta$ -lactam antibiotics in *Helicobacter pylori*. *Antimicrob Agents Chemother* 2002;**46**:2229-33.
- 68 **van Zwet AA**, Vandenbroucke-Grauls CM, Thijs JC, *et al*. Stable amoxicillin resistance in *Helicobacter pylori*. *Lancet* 1998;**352**:1595.
- 69 **Deloney CR**, Schiller NL. Characterization of an *in vitro*-selected amoxicillin-resistant strain of *Helicobacter pylori*. *Antimicrob Agents Chemother* 2000;**44**:3368-73.
- 70 **Okamoto T**, Yoshiyama H, Nakazawa T, *et al*. A change in PBP1 is involved in amoxicillin resistance of clinical isolates of *Helicobacter pylori*. *J Antimicrob Chemother* 2002;**50**:849-56.
- 71 **Paul R**, Postius S, Melchers K, *et al*. Mutations of the *Helicobacter pylori* genes *rdxA* and *pbp1* cause resistance against metronidazole and amoxicillin. *Antimicrob Agents Chemother* 2001;**45**:962-5.
- 72 **Dore MP**, Graham DY, Sepulveda AR. Different penicillin-binding protein profiles in amoxicillin-resistant *Helicobacter pylori*. *Helicobacter* 1999;**4**:154-61.
- 73 **Kwon DH**, Dore MP, Kim JJ, *et al*. High-level  $\beta$ -lactam resistance associated with acquired multidrug resistance in *Helicobacter pylori*. *Antimicrob Agents Chemother* 2003;**47**:2169-78.
- 74 **Godoy APO**, Ribeiro ML, Benvengo YHB, *et al*. Analysis of antimicrobial susceptibility and virulence factors in *Helicobacter pylori* clinical isolates. *BMC Gastroenterol* 2003;**3**:20.
- 75 **Wu H**, Shi XD, Wang HT, *et al*. Resistance of *Helicobacter pylori* to metronidazole, tetracycline and amoxicillin. *J Antimicrob Chemother* 2000;**46**:121-3.
- 76 **Trieber CA**, Taylor DE. Mutations in the 16S rRNA genes of *Helicobacter pylori* mediate resistance to tetracycline. *J Bacteriol* 2002;**184**:2131-40.
- 77 **Gerrits MM**, de Zoete MR, Arents NL, *et al*. 16S rRNA mutation-mediated tetracycline resistance in *Helicobacter pylori*. *Antimicrob Agents Chemother* 2002;**46**:2996-3000.
- 78 **Dailidienė D**, Bertoli MT, Miculevičienė J, *et al*. Emergence of tetracycline resistance in *Helicobacter pylori*: multiple mutational changes in 16S ribosomal DNA and other genetic loci. *Antimicrob Agents Chemother* 2002;**46**:3940-6.
- 79 **Gerrits MM**, Berning M, Van Vliet AH, *et al*. Effects of 16S rRNA gene mutations on tetracycline resistance in *Helicobacter pylori*. *Antimicrob Agents Chemother* 2003;**47**:2984-6.
- 80 European Study Group on Antibiotic Susceptibility of *Helicobacter pylori*. Results of a Multicentre European Survey in 1991 of metronidazole resistance in *Helicobacter pylori*. *Eur J Clin Microbiol Infect Dis* 1992;**9**:777-81.
- 81 **Glupczynski Y**, Broutet N, Cantagrel A, *et al*. Comparison of the E test and agar dilution method for antimicrobial susceptibility testing of *Helicobacter pylori*. *Eur J Clin Microbiol Infect Dis* 2002;**21**:549-52.
- 82 **Mendz GL**, Mégraud F. Is the molecular basis of metronidazole resistance in microaerophilic organisms understood? *Trends Microbiol* 2002;**10**:370.
- 83 **Chisholm SA**, Owen RJ. Mutations in *Helicobacter pylori* *rdxA* gene sequences may not contribute to metronidazole resistance. *J Antimicrob Chemother* 2003;**51**:995-9.
- 84 **Marais A**, Bilardi C, Cantet F, *et al*. Characterization of the genes *rdxA* and *frxA* involved in metronidazole resistance in *Helicobacter pylori*. *Res Microbiol* 2003;**154**:137-44.

- 85 **Moore RA**, Beckthold B, Wong S, *et al*. Nucleotide sequence of the *gyrA* gene and characterization of ciprofloxacin-resistant mutants of *Helicobacter pylori*. *Antimicrob Agents Chemother* 1995;**39**:107–11.
- 86 **Tankovic J**, Lascols C, Sculo Q, *et al*. Single and double mutations in *gyrA* but not in *gyrB* are associated with low- and high-level fluoroquinolone resistance in *Helicobacter pylori*. *Antimicrob Agents Chemother* 2003;**47**:3942–4.
- 87 **Heep M**, Beck D, Bayerdorffer E, *et al*. Rifampin and rifabutin resistance mechanism in *Helicobacter pylori*. *Antimicrob Agents Chemother* 1999;**43**:1497–9.
- 88 **Fujimura S**, Kato S, Kawamura T, *et al*. *In vitro* activity of rifampicin against *Helicobacter pylori* isolated from children and adults. *J Antimicrob Chemother* 2002;**49**:541–3.
- 89 **Heep M**, Rieger U, Beck D, *et al*. Mutations in the beginning of the *rpoB* gene can induce resistance to rifamycins in both *Helicobacter pylori* and *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 2000;**44**:1075–7.
- 90 **Heep M**, Beck D, Bayerdorffer E, *et al*. Rifampin and rifabutin resistance mechanism in *Helicobacter pylori*. *Antimicrob Agents Chemother* 1999;**43**:1497–9.
- 91 **Heep M**, Rieger U, Beck D, *et al*. Mutations in the beginning of the *rpoB* gene can induce resistance to rifamycins in both *Helicobacter pylori* and *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 2000;**44**:1075–7.
- 92 **Mégraud F**, Doermann HP. Clinical relevance of resistant strains of *Helicobacter pylori*: a review of current data. *Gut* 1998;**43**:S61–5.
- 93 **Houben MHMG**, van de Beek D, Hensen EF, *et al*. A systematic review of *Helicobacter pylori* eradication therapy – the impact of antimicrobial resistance on eradication rates. *Aliment Pharmacol Ther* 1999;**13**:1047–55.
- 94 **Bochenek WJ**, Peters S, Fraga PD, *et al*. *Helicobacter pylori* Pantoprazole Eradication (HELPE) Study Group. Eradication of *Helicobacter pylori* by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. *Helicobacter* 2003;**8**:626–42.
- 95 **Ducons JA**, Santolaria S, Guirao R, *et al*. Impact of clarithromycin resistance on the effectiveness of a regimen for *Helicobacter pylori*: a prospective study of 1-week lansoprazole, amoxicillin and clarithromycin in active peptic ulcer. *Aliment Pharmacol Ther* 1999;**13**:775–80.
- 96 **Hoshiya S**, Watanabe K, Tokunaga K, *et al*. Relationship between eradication therapy and clarithromycin-resistant *Helicobacter pylori* in Japan. *J Gastroenterol* 2000;**35**:10–14.
- 97 **Kalach N**, Benhamou PH, Campeotto F, *et al*. Clarithromycin resistance and eradication of *Helicobacter pylori* in children. *Antimicrob Agents Chemother* 2001;**45**:2134–5.
- 98 **Katlaris PH**, Forbes GM, Talley NJ, *et al*. A randomized comparison of quadruple and triple therapies for *Helicobacter pylori* eradication: the QUADRATE study. *Gastroenterology* 2002;**123**:1763–9.
- 99 **Kawabata H**, Habu Y, Tomioka H, *et al*. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of *Helicobacter pylori* infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. *Aliment Pharmacol Ther* 2003;**17**:259–64.
- 100 **Kihira K**, Satoh K, Saifuku K, *et al*. Rabeprazole, amoxicillin and low- or high-dose clarithromycin for cure of *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2000;**14**:1083–7.
- 101 **Lamouliatte H**, the Aquitaine Gastro Association, Samoyeau R, *et al*. Double vs. single dose of pantoprazole in combination with clarithromycin and amoxicillin for 7 days, in eradication of *Helicobacter pylori* in patients with non-ulcer dyspepsia. *Aliment Pharmacol Ther* 1999;**13**:1523–30.
- 102 **Lamouliatte H**, Mégraud F, Delchier JC, *et al*. Second-line treatment for failure to eradicate *Helicobacter pylori*: a randomized trial comparing four treatment strategies. *Aliment Pharmacol Ther* 2003;**18**:791–7.
- 103 **Lehmann FS**, Drewe J, Terracciano L, *et al*. Effect of arnidazole and clarithromycin resistance on eradication of *Helicobacter pylori* in peptic ulcer disease. *Aliment Pharmacol Ther* 2000;**14**:305–9.
- 104 **Lind T**, Mégraud F, Unge P, *et al*. The MACH2 study: role of omeprazole in eradication of *Helicobacter pylori* with 1-week triple therapies. *Gastroenterology* 1999;**116**:248–53.
- 105 **McMahon BJ**, Hennessy TW, Bensler JM, *et al*. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for *Helicobacter pylori* infections. *Ann Intern Med* 2003;**139**:463–9.
- 106 **Miki I**, Aoyama N, Sakai T, *et al*. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of *Helicobacter pylori* infection with lansoprazole- or rabeprazole-based triple therapy in Japan. *Eur J Gastroenterol Hepatol* 2003;**15**:27–33.
- 107 **Murakami K**, Sato R, Okimoto T, *et al*. Eradication rates of clarithromycin-resistant *Helicobacter pylori* using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. *Aliment Pharmacol Ther* 2002;**16**:1933–8.
- 108 **Peitz U**, Sulliga M, Wolle K, *et al*. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure *Helicobacter pylori* infection: impact of two second-line therapies in a randomized study. *Aliment Pharmacol Ther* 2002;**16**:315–24.
- 109 **Pilotto A**, Leandro G, Franceschi M, *et al*. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against *Helicobacter pylori*. *Aliment Pharmacol Ther* 1999;**13**:667–73.
- 110 **Poon SK**, Chang CS, Su J, *et al*. Primary resistance to antibiotics and its clinical impact on the efficacy of *Helicobacter pylori* lansoprazole-based triple therapies. *Aliment Pharmacol Ther* 2002;**16**:291–6.
- 111 **Tankovic J**, Lamarque D, Lascols C, *et al*. Impact of *Helicobacter pylori* resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy. *Aliment Pharmacol Ther* 2001;**15**:707–13.
- 112 **Bazzoli F**, Zagari M, Pozzato P, *et al*. Evaluation of short-term low-dose triple therapy for the eradication of *Helicobacter pylori* by factorial design in a randomized, double-blind, controlled study. *Aliment Pharmacol Ther* 1998;**12**:439–45.
- 113 **Ellenrieder V**, Boeck W, Richter C, *et al*. Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of *Helicobacter pylori* eradication. *Scand J Gastroenterol* 1999;**34**:750–6.
- 114 **Hurenkamp GJ**, van der Ende A, Grundmeijer HG, *et al*. Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate *Helicobacter pylori* infection in patients with ulcer disease. *Aliment Pharmacol Ther* 2000;**14**:1065–70.
- 115 **Savarino V**, Zentilin P, Pivari M, *et al*. The impact of antibiotic resistance on the efficacy of three 7-day regimens against *Helicobacter pylori*. *Aliment Pharmacol Ther* 2000;**14**:893–900.
- 116 **Bardhan KD**, Morton D, Perry MJ, *et al*. Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of *Helicobacter pylori*. *Aliment Pharmacol Ther* 2001;**15**:1199–204.
- 117 **Sung JJJ**, Chn FKL, Wu JCY, *et al*. One-week ranitidine bismuth citrate in combinations with metronidazole, amoxicillin and clarithromycin in the treatment of *Helicobacter pylori* infection: the RBC-MACH study. *Aliment Pharmacol Ther* 1999;**13**:1079–84.
- 118 **Mégraud F**, Roberts P, Williamson R. Ranitidine bismuth citrate can help to overcome *Helicobacter pylori* resistance to clarithromycin *in vivo*. *Helicobacter* 2000;**5**:222–6.
- 119 **O'Morain C**, Borody T, Farley A, *et al*. Efficacy and safety of single-triple capsules of bismuth biscalcitrates, metronidazole and tetracycline, given with omeprazole, for the eradication of *Helicobacter pylori*: an international multicentre study. *Aliment Pharmacol Ther* 2003;**17**:415–20.
- 120 **Bardhan K**, Bayerdorffer E, Veldhuyzen Van Zanten SJ, *et al*. The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure *Helicobacter pylori* infection. *Helicobacter* 2000;**5**:196–201.
- 121 **Bayerdorffer E**, Lonovics J, Dite P, *et al*. Efficacy of two different dosage regimens of omeprazole, amoxicillin and metronidazole for the cure of *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 1999;**13**:1639–45.
- 122 **Isomoto H**, Inoue K, Furusu H, *et al*. High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for *Helicobacter pylori* infection. *Aliment Pharmacol Ther* 2003;**18**:101–7.
- 123 **Murakami K**, Sato R, Okimoto T, *et al*. Eradication rates of clarithromycin-resistant *Helicobacter pylori* using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. *Aliment Pharmacol Ther* 2002;**16**:1933–8.
- 124 **Miwa H**, Nagahara A, Kurosawa A, *et al*. Is antimicrobial susceptibility testing necessary before second-line treatment for *Helicobacter pylori* infection? *Aliment Pharmacol Ther* 2003;**17**:1545–51.
- 125 **Neri M**, Milano A, Laterza F, *et al*. Role of antibiotic sensitivity testing before first-line *Helicobacter pylori* eradication treatments. *Aliment Pharmacol Ther* 2003;**18**:821–7.
- 126 **Romano M**, Iovene MR, Montella F, *et al*. Pretreatment antimicrobial-susceptibility testing in the eradication of *H. pylori* infection. *Am J Gastroenterol* 2000;**95**:3317–18.
- 127 **Toracchio S**, Cellini L, Di Campli E, *et al*. Role of antimicrobial susceptibility testing on efficacy of triple therapy in *Helicobacter pylori* eradication. *Aliment Pharmacol Ther* 2000;**14**:1639–43.
- 128 **Hua JS**, Zheng PY, Fong TK, *et al*. *Helicobacter pylori* acquisition of metronidazole resistance by natural transformation *in vitro*. *World J Gastroenterol* 1998;**4**:385–7.
- 129 **Grignon B**, Tankovic J, Mégraud F, *et al*. Validation of diffusion methods for macrolide susceptibility testing of *Helicobacter pylori*. *Microb Drug Res* 2002;**8**:61–6.
- 130 **Owen RJ**. Molecular testing for antibiotic resistance in *Helicobacter pylori*. *Gut* 2002;**50**:285–9.
- 131 **Versalovic J**, Shortridge D, Kliber K, *et al*. Mutations in 23S rRNA are associated with clarithromycin resistance in *Helicobacter pylori*. *Antimicrob Agents Chemother* 1996;**40**:477–80.
- 132 **Occhialini A**, Urdaci M, Doucet-Populaire F, *et al*. Macrolide resistance in *Helicobacter pylori*: rapid detection of point mutations and assays of macrolide binding to ribosomes. *Antimicrob Agents Chemother* 1997;**41**:2724–8.
- 133 **Stone GG**, Shortridge D, Versalovic J, *et al*. A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant *Helicobacter pylori*. *Antimicrob Agents Chemother* 1997;**41**:712–14.
- 134 **Pina M**, Occhialini A, Monteiro L, *et al*. Detection of point mutations associated with resistance of *Helicobacter pylori* to clarithromycin by hybridization in liquid phase. *J Clin Microbiol* 1998;**36**:3285–90.
- 135 **Marais A**, Monteiro L, Occhialini A, *et al*. Direct detection of *Helicobacter pylori* resistance to macrolides by a polymerase chain reaction/DNA enzyme immunoassay in gastric biopsy specimens. *Gut* 1999;**44**:463–7.
- 136 **Maeda S**, Yoshida H, Matsunaga H, *et al*. Detection of clarithromycin-resistant *H. pylori* strains by a preferential homoduplex formation assay. *J Clin Microbiol* 2000;**38**:210–14.
- 137 **van Doorn LJ**, Debets-Ossenkopp YJ, Marais A, *et al*. Rapid detection, by PCR and reverse hybridization, of mutations in the *Helicobacter pylori* 23S rRNA gene, associated with macrolide resistance. *Antimicrob Agents Chemother* 1999;**43**:1779–82.
- 138 **Alarcón T**, Domingo D, Prieto N, *et al*. PCR using 3'-mismatched primers to detect A2142C mutation in 23S rRNA conferring resistance to clarithromycin in *Helicobacter pylori* clinical isolates. *J Clin Microbiol* 2000;**38**:923–5.
- 139 **Scarpellini P**, Carrera P, Cavallero A, *et al*. Direct detection of *Helicobacter pylori* mutations associated with macrolide resistance in gastric biopsy

- material taken from human immunodeficiency virus-infected subjects. *J Clin Microbiol* 2002;**40**:2234–7.
- 140 **Gibson JR**, Saunders NA, Burke B, *et al.* Novel method for rapid determination of clarithromycin sensitivity in *Helicobacter pylori*. *J Clin Microbiol* 1999;**37**:3746–8.
- 141 **Chisholm SA**, Owen RJ, Teare EL, *et al.* PCR-based diagnosis of *Helicobacter pylori*: infection and real-time determination of clarithromycin resistance directly from human gastric biopsy samples. *J Clin Microbiol* 2001;**39**:1217–20.
- 142 **Matsumura M**, Hikiba Y, Ogura K, *et al.* Rapid detection of mutations in the 23S rRNA gene of *Helicobacter pylori* that confers resistance to clarithromycin treatment to the bacterium. *J Clin Microbiol* 2001;**39**:691–5.
- 143 **Oleastro M**, Ménard A, Santos A, *et al.* Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in *Helicobacter pylori*. *J Clin Microbiol* 2003;**41**:397–402.
- 144 **Lascols C**, Lamarque D, Costa JM, *et al.* Fast and accurate quantitative detection of *Helicobacter pylori* and identification of clarithromycin resistance mutations in *H. pylori* isolates from gastric biopsy specimens by real-time PCR. *J Clin Microbiol* 2003;**41**:4573–7.
- 145 **Trebesius K**, Panthel K, Strobel S, *et al.* Rapid and specific detection of *Helicobacter pylori* macrolide resistance in gastric tissue by fluorescent *in situ* hybridisation. *Gut* 2000;**46**:608–14.
- 146 **Wittwer CT**, Ririe KM, Andrew RV, *et al.* The Lightcycler™: a microvolume multisample fluorimeter with rapid temperature control. *BioTechniques* 1997;**22**:176–81.
- 147 **Schabereiter-Gurtner C**, Dragosics B, Puz S, *et al.* Detection of *Helicobacter pylori* infection and determination of clarithromycin resistance in stool specimens by real-time PCR. *Helicobacter* 2003;**8**:480.
- 148 **Ménard A**, Santos A, Mégraud F, *et al.* PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with *Helicobacter pylori* resistance to clarithromycin. *Antimicrob Agents Chemother* 2002;**46**:1156–7.
- 149 **Russmann H**, Kempf VA, Koletzko S, *et al.* Comparison of fluorescent *in situ* hybridization and conventional culturing for detection of *Helicobacter pylori* in gastric biopsy specimens. *J Clin Microbiol* 2001;**39**:304–8.
- 150 **Feydt-Schmidt A**, Russmann H, Lehn N, *et al.* Fluorescence *in situ* hybridization vs. epilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant *Helicobacter pylori* strains in gastric biopsies from children. *Aliment Pharmacol Ther* 2002;**16**:2073–9.
- 151 **Russmann H**, Feydt-Schmidt A, Adler K, *et al.* Detection of *Helicobacter pylori* in paraffin-embedded and in shock-frozen gastric biopsy samples by fluorescent *in situ* hybridization. *J Clin Microbiol* 2003;**41**:813–15.
- 152 **Latham SR**, Owen RJ, Elviss NC, *et al.* Differentiation of metronidazole-sensitive and -resistant clinical isolates of *Helicobacter pylori* by immunoblotting with antisera to the RdxA protein. *J Clin Microbiol* 2001;**39**:3052–5.
- 153 **Latham SR**, Labigne A, Jenks PJ. Production of the RdxA protein in metronidazole-susceptible and -resistant isolates of *Helicobacter pylori* cultured from treated mice. *J Antimicrob Chemother* 2002;**49**:675–8.
- 154 **Pelerito A**, Oleastro M, Labigne A, *et al.* Analysis of *Helicobacter pylori*'s penicillin-binding proteins (PBPs) natural polymorphism, therapeutic targets of the family of  $\beta$ -lactam antibiotics. *Helicobacter* 2003;**8**:394.